Denali Therapeutics is a commercial-stage biotech built around solving the blood–brain barrier problem using its proprietary Transport Vehicle platform, which engineers biologics to leverage endogenous receptor pathways (notably transferrin receptor) to shuttle therapeutic payloads into the CNS. The investment profile shifted materially on March 25, 2026, when the FDA granted accelerated approval to AVLAYAH (tividenofusp alfa-eknm) for neurologic manifestations of Hunter syndrome—described as the first BBB-designed biologic approved for this setting and a pivotal validation of Denali’s platform thesis. Post-approval, Denali is transitioning from milestone-driven revenue to product-based specialty pharma revenue, recording initial product revenue beginning in Q2 2026, while still benefiting from strategic collaborations with partners such as Biogen, Sanofi, and Takeda (historically). Near-term focus is the U.S. ultra-orphan market where reimbursement dynamics are most supportive; medium-term growth includes EU regulatory filings and broader global expansion. Denali’s pipeline is organized by delivery modality (ETV/ATV/OTV) spanning rare pediatric lysosomal disorders and large neurodegenerative indications, with physician adoption driven by the key differentiator versus traditional therapies: whole-body treatment that addresses CNS decline rather than only peripheral symptoms. The report frames AVLAYAH as the de-risking event that converts Denali from a binary platform bet into a scalable CNS delivery company, while highlighting that success now hinges on launch execution, confirmatory data, and upcoming neurodegenerative readouts.

Denali Therapeutics Inc (DNLI) Investment Analysis:

1. Executive Summary

Denali Therapeutics Inc. (DNLI) is a pioneering, commercial-stage biotechnology company that has dedicated its scientific and corporate identity to solving the most intractable challenge in neurobiology: the blood-brain barrier (BBB). Historically, the BBB has served as an evolutionary defense mechanism, preventing over 98% of small molecules and nearly 100% of large-molecule biologics from reaching the central nervous system (CNS) in therapeutically relevant concentrations. Denali's core strategic thesis is built upon its proprietary Transport Vehicle (TV) platform, a modular technology that hijacks endogenous receptor-mediated transport pathways to "shuttle" therapeutic payloads into the brain. On March 25, 2026, the company fundamentally altered its investment profile by securing U.S. Food and Drug Administration (FDA) accelerated approval for AVLAYAH™ (tividenofusp alfa-eknm), the first biologic specifically designed to cross the BBB for the treatment of neurologic manifestations of Hunter syndrome (MPS II).[1, 2]

The company generates revenue through a multi-faceted model that includes direct product sales, high-value strategic collaborations with "Big Pharma" partners, and synthetic royalty financing. Following the approval of AVLAYAH, Denali has transitioned into a commercial organization, recording its first product-related revenue in the second quarter of 2026. Prior to this, the company relied on milestone payments and cost-sharing from partners such as Biogen, Sanofi, and Takeda Pharmaceutical.[3, 4, 5] Geographically, the company is currently focused on the United States, which represents the largest market for ultra-orphan diseases due to favorable reimbursement pathways and a concentration of specialized treatment centers. However, global expansion is a critical component of the five-year growth plan, with regulatory filings expected in Europe by late 2026 and clinical trials active in South America.[2, 6, 7]

Denali's core products are categorized by their delivery modality within the Transport Vehicle platform: Enzyme Transport Vehicles (ETV) for lysosomal storage disorders, Antibody Transport Vehicles (ATV) for neurodegenerative proteinopathies like Alzheimer's, and Oligonucleotide Transport Vehicles (OTV) for precision gene modulation. Its primary customer types are specialty pharmacies and academic medical centers that treat pediatric patients with rare genetic disorders and, increasingly, neurology practices managing chronic conditions like Parkinson's disease. The most important end markets include the approximately 2,000 individuals globally with Hunter syndrome and the millions suffering from Alzheimer’s and Parkinson’s.[1, 8, 9] Customers and physicians choose Denali over alternatives—primarily traditional enzyme replacement therapies—because Denali’s products offer "whole-body" treatment, addressing the catastrophic cognitive and behavioral decline that standard therapies leave untouched.[1, 10, 11]

2. Business Drivers & Strategic Overview

The economic engine of Denali Therapeutics is fueled by the clinical validation of the Transport Vehicle platform. The strategic significance of the AVLAYAH approval cannot be overstated; it serves as a "proof-of-concept" for the entire ETV franchise, suggesting that the engineering of Fc domains to bind the transferrin receptor (TfR) is a repeatable, modular success. This validation has transformed Denali from a high-risk research "bet" into a platform company with a defensible moat and a clear path to category leadership in CNS medicine.[1, 12, 13]

Product and Service Detail: The TV Platform Mechanism

Denali's actual "product" is the engineering expertise applied to large molecules to facilitate receptor-mediated transcytosis (RMT). The TV platform utilizes an engineered Fc domain that binds to the transferrin receptor, which is highly expressed on the surface of brain endothelial cells. Once bound, the receptor internalizes the drug and transports it across the cell into the brain parenchyma. In preclinical models, this technology has demonstrated 10- to 30-fold greater brain exposure compared to standard enzymes or antibodies.[4, 10, 14]

Franchise	Mechanism	Lead Product	Clinical Status (as of April 2026)
ETV (Enzyme)	Replaces missing enzymes in LSDs	AVLAYAH™	Approved (Hunter Syndrome); DNL126 (Phase 1/2, Sanfilippo A)
ATV (Antibody)	Enhances plaque clearance; lowers ARIA risk	DNL921	Phase 1 (Alzheimer's)
OTV (Oligonucleotide)	Modulates gene expression in CNS	DNL628	Phase 1b (Alzheimer's - MAPT/tau)
Small Molecules	Targets genetic drivers (Kinase inhibitors)	BIIB122	Phase 2b LUMA (Parkinson's)

Denali's service offering includes "Denali Patient Services," a high-touch commercial support system. This is a strategic necessity for ultra-orphan drugs, where the patient journey—from genetic diagnosis to insurance authorization and weekly intravenous infusion—is fraught with friction. By managing these logistics, Denali ensures higher adherence rates and minimizes "leakage" to traditional ERTs.[2, 7]

Moat Analysis: Barriers to Entry and Ecosystem Advantages

Denali has constructed a multi-layered moat that combines technical, legal, and economic barriers:

1. Intellectual Property (IP) and Proprietary Engineering: The company holds over 500 patents worldwide covering the specific amino acid modifications in the Fc region required for TfR binding.[6] A major technical hurdle for competitors is that high-affinity binding to TfR can sequester the receptor, preventing natural iron transport and leading to systemic iron deficiency. Denali’s "sweet spot" engineering allows for efficient transport without interfering with iron homeostasis, a difficult balance to replicate without infringing on their core patents.[4, 8, 15]
2. Modular Scale Advantage: The TV platform is inherently modular. The delivery vehicle used for AVLAYAH (DNL310) is fundamentally similar to the one used for DNL126 (Sanfilippo A) and DNL952 (Pompe). This allows Denali to advance multiple candidates with reduced developmental risk and faster timelines, as the safety profile of the delivery vehicle has been established.[8, 12]
3. High Switching Costs and Physician Loyalty: In rare pediatric diseases, the risk of therapeutic switching is extraordinarily low once a patient is stabilized on an effective treatment. If AVLAYAH prevents cognitive decline in a child, a physician is ethically and practically discouraged from switching to a non-BBB-crossing alternative, creating a lifetime revenue stream for Denali.[15]
4. Regulation and First-Mover Advantage: By securing accelerated approval through a surrogate biomarker (CSF heparan sulfate reduction), Denali has set the regulatory standard for this class of drugs. This "biomarker path" serves as a hurdle for competitors who may be required to prove clinical outcomes, a much longer and more expensive process.[1, 16]

TAM / Market Opportunity Analysis

The market opportunity for Denali spans from ultra-rare orphan diseases to the largest unmet needs in global health.

• Hunter Syndrome (MPS II): The global market was valued at $1.05 billion in 2025 and is projected to grow to $1.81 billion by 2034.[17] With ~500 U.S. patients and ~2,000 globally, and a treatment cost exceeding $500,000 per year, this represents a multi-hundred-million-dollar peak revenue opportunity for Denali as it displaces traditional ERTs.[1, 18]
• Sanfilippo Syndrome Type A (MPS IIIA): This market is expected to reach $15.02 billion by 2030, growing at a CAGR of 10.2%.[9] There are currently no approved treatments, making DNL126 a potential blockbuster if it follows the accelerated approval path of AVLAYAH.[19, 20]
• Neurodegenerative (Parkinson’s and Alzheimer’s): These are multi-billion-dollar segments. The Parkinson's drug market is expected to reach $9.2 billion by 2030.[21] Denali’s LRRK2 program (BIIB122) addresses a genetically validated target present in 1-2% of all cases, but potentially broader if LRRK2 inhibition proves neuroprotective in idiopathic patients.[22, 23]

Competitive Landscape

Denali is currently a leader in the RMT biologic space but faces several distinct types of competitors:

1. Roche (The Primary Technical Competitor): Roche's "Brainshuttle" technology is the most direct threat. Its lead candidate, trontinemab, is currently in Phase 3 trials for Alzheimer's.[24, 25] Roche has presented data showing 91-92% amyloid clearance with low ARIA incidence.[26, 27] While Roche is focused on the high-volume Alzheimer's market, Denali has secured a lead in the orphan LSD market.
2. JCR Pharmaceuticals: A Japanese competitor whose Hunter treatment (Izcargo) is approved in Japan.[11, 28] While ahead in Asia, JCR lacks the commercial footprint and broader OTV/ATV platform diversity that Denali possesses in Western markets.
3. Gene Therapy (The "Disruptive" Competitor): Companies like Ultragenyx and Abeona are pursuing AAV-based gene therapies for MPS IIIA.[20, 29] Gene therapy offers the threat of a "one-and-done" treatment, which could significantly erode the market for chronic weekly infusions if proven safe and durable over decades.
4. Traditional ERT (The "Incumbent" Competitor): Takeda's Elaprase remains the incumbent in Hunter syndrome. Denali is gaining ground by highlighting Elaprase's inability to treat brain symptoms, a critical clinical differentiator that has led to favorable analyst sentiment and rapid expected adoption.[10, 30]

Denali appears to be gaining ground following the AVLAYAH approval, which removes the "binary" platform risk that previously weighed on the stock. The decision by Takeda to return full rights to DNL593 (FTD-GRN) in April 2026 is viewed by the analysis as a strategic consolidation for Denali, albeit one that increases near-term burn.[31, 32, 33]

3. Financial Performance & Valuation

Denali Therapeutics’ financial profile is characterized by the high R&D intensity of a platform-biotech, now transitioning into a revenue-generating entity.

Latest Quarterly Financial Results (Q4 2025)

The company reported its full-year 2025 and fourth-quarter results on February 26, 2026.[5, 34]

• Announcement Date: February 26, 2026.
• Earnings Per Share (EPS): Reported -$0.73 per share, which beat analyst consensus of -$0.75 by $0.02.[35, 36]
• Revenue: Reported $0.00 for the quarter, missing expectations of $2.67 million. This was expected by informed investors, as commercial sales of AVLAYAH had not yet commenced.[37, 38]
• Net Loss: $128.5 million for Q4 2025 and $512.5 million for the full year 2025. This compares to a net loss of $422.8 million in FY 2024.[5]
• R&D Expenses: Totaled $418.8 million in 2025, an increase of $22.4 million over 2024, driven by the ramp-up of multiple TV clinical programs and the operation of the manufacturing facility in Salt Lake City.[5]
• G&A Expenses: Increased 31% to $136.6 million, primarily due to "launch readiness" activities for tividenofusp alfa.[5]

Management Commentary and Guidance

During the February 26 earnings call, CEO Ryan Watts emphasized that 2025 was a year of "commercial readiness," while 2026 would be the "year of the launch".[5] Management confirmed that the Salt Lake City facility is operational and will provide long-term gross margin advantages through insourced manufacturing.[5] Following the early FDA approval on March 25, management commentary shifted to insurance coverage and patient identification. Notably, the company has not provided formal 2026 revenue guidance, a common practice for ultra-orphan launches where the first 2-3 quarters are highly variable.[3, 5]

Impact on Stock Price and Analyst Sentiment

The AVLAYAH approval had a meaningful positive impact. The stock surged 4.5% immediately following the March 25 announcement and is up 27% year-to-date as of late April 2026.[39] Analyst recommendations have remained overwhelmingly positive, with 87-89% "Buy" or "Strong Buy" ratings.[38, 40, 41] Following the approval, several firms raised their price targets:
* Stifel: Raised to $41 from $34.[30]
* Goldman Sachs: Raised to $40.[30, 42]
* Morgan Stanley: Raised to $42.[42, 43]
* HC Wainwright: Maintained $42 despite lowering long-term EPS forecasts.[42, 44]

Valuation Multiples and Financial Drivers

Traditional P/E multiples are not relevant for Denali at this stage. Instead, valuation is driven by its cash-adjusted pipeline value and its Price-to-Book (P/B) ratio.

Metric	Denali (DNLI)	Sector Median	Peer Average
P/B Ratio	3.08x	2.28x	21.45x
Cash Runway	~2.5 Years	Varies	Varies
Trailing 12m FCF	-$422.1M	N/A	N/A

The most important financial driver for valuation is the 5-year sales growth, currently forecasted by analysts at an average of 50.1% annually through the initial launch phase.[45] Valuation is inextricably linked to the "platform value" of the TV technology; the approval of AVLAYAH effectively "de-risks" the estimated $1 billion+ peak opportunity in the rare disease enzyme franchise.[15]

A Discounted Cash Flow (DCF) model points to an intrinsic value of $33.81, suggesting that at current levels (~$19.45), the stock is significantly undervalued by the market, which is still pricing in a "clinical stage" discount despite the move to commercialization.[46]

4. Risk Assessment & Macroeconomic Considerations

The investment thesis for Denali, while robust, is subject to high-convexity risks.

Company-Specific Execution Risks

• Commercial Launch Failure: Denali is a first-time commercial entrant. There is no guarantee that they can successfully convert the existing Hunter syndrome patient base from Takeda's Elaprase. A "slow launch" (e.g., fewer than 50 patients in Year 1) would likely lead to a significant valuation contraction.[15, 30]
• Confirmatory Trial Risk: The accelerated approval of AVLAYAH is contingent on the Phase 2/3 COMPASS study. If this study fails to demonstrate clinical benefit (e.g., improvement in cognitive scores) despite the biomarker success, the FDA could withdraw the drug from the market.[1, 2]
• Pipeline Concentration: Following Takeda's termination of the DNL593 deal, Denali is now responsible for 100% of the costs for this Phase 1/2 asset. While the potential reward is higher, it increases the risk that a failure in this specific program could drain cash reserves.[13, 31, 33]

Competitive and Industry Structure Risks

• Gene Therapy Disruption: The most significant industry risk is the rapid advancement of gene therapies. If a one-time treatment for Sanfilippo or Hunter syndrome is approved before 2030, the multi-decade revenue stream of Denali's chronic ERT model could be decimated.[9, 20, 29]
• Platform Competition: If Roche’s trontinemab demonstrates superior brain distribution or a safer profile (zero ARIA) in its Phase 3 Alzheimer's trials, Denali’s ATV platform may struggle to find a partner or achieve favorable licensing terms.[24, 25, 47]

Regulatory and Legal Risks

• Safety Profile (Boxed Warning): AVLAYAH’s label includes a boxed warning for anaphylaxis and life-threatening allergic reactions.[7, 16] While common for ERTs, any cluster of severe safety events in the real-world setting could lead to "Dear Doctor" letters or clinical holds on other TV programs.[2]
• IP Litigation: As Denali moves from R&D to a $3B+ market cap, it becomes a target for patent trolls or competitors seeking to invalidate its TfR-binding claims. Protecting these claims in international courts is a costly and uncertain endeavor.[6, 15]

Balance Sheet / Capital Allocation Risks

• Dilution: With a FY 2025 net loss of $512.5 million, Denali’s ~$1 billion in cash provides roughly 24 months of runway.[5] Unless milestone payments from Biogen or Sanofi trigger in 2026-2027, the company will likely need another dilutive capital raise.[5, 13]
• Manufacturing Over-Extension: Investing heavily in the Salt Lake City facility is a long-term play for margin. However, in the short term, it consumes capital that could have been used to accelerate earlier-stage assets.[5]

Macroeconomic Sensitivities

• Capital Markets Volatility: Biotech is highly sensitive to the cost of equity. A sustained period of high interest rates would reduce the "present value" of Denali's long-term neurodegenerative pipeline, even if the clinical data is positive.[5, 48]
• Drug Pricing Legislation: In the U.S., the potential for legislation capping the price of orphan drugs is a persistent "overhang." A price of $800,000/year for a child's treatment is a politically sensitive target.[18, 49]

Warning Signs and Long-term Damage

• What could go wrong: A mid-2026 failure of the Biogen LRRK2 LUMA study would be the most damaging event, as it would suggest the TV platform cannot address the larger, complex neurodegenerative markets.[5, 15]
• Early Warning Sign: Any downward revision in the "87% Buy" analyst consensus or a sudden departure of key scientific founders like Ryan Watts would signal internal or regulatory distress.[40, 50]

SIGNIFICANT EXECUTION OVERHANG.

5. 5-Year Scenario Analysis

Predicting the share price of a platform biotech 5 years out requires assessing the velocity of the commercial launch and the probability of success (PoS) for late-stage clinical readouts.

Key Fundamental Assumptions

• Current Share Price: $19.45.[40, 51]
• Current Shares Outstanding: 158.6 million.[15, 52]
• Year 5 Revenue Target: Driven by (Hunter Rev + Sanfilippo Rev + Parkinson's Royalties).
• Exit Multiple: Based on commercial-stage biotech P/S (Price-to-Sales) averages of 6x - 12x depending on pipeline depth.

Scenario Projections

Scenario	Year 5 Rev (2031)	Margin / EPS Assumption	Valuation Multiple	Current Price	Implied 2031 Price	5-Year Return	Annualized Return	Prob.
High Case	$1.2 Billion	20% Net Margin / $1.50 EPS	12x P/S	$19.45	$85.00	+337%	34.3%	20%
Base Case	$550 Million	Break-even / $0.00 EPS	8x P/S	$19.45	$32.00	+64%	10.4%	55%
Low Case	$150 Million	Net Loss (-$2.50 EPS)	4x P/S	$19.45	$5.00	-74%	-24.1%	25%

Narrative Bridge to Valuations

High Case (20% Probability):
In this scenario, AVLAYAH reaches peak sales of $600M by 2031, capturing 60% of the U.S. and 30% of the global Hunter market. DNL126 (Sanfilippo A) launches in 2028 and adds another $400M in revenue. Crucially, the Parkinson's (BIIB122) program is successful in Phase 2/3, triggering $200M+ in annual royalties and milestones from Biogen. Denali achieves GAAP profitability by 2030. The market applies a premium 12x P/S multiple to reflect a fully validated platform that is now entering the Alzheimer's market with its OTV/ATV assets.[3, 4, 15, 53]

Base Case (55% Probability):
AVLAYAH launch is steady but competitive, reaching $250M in revenue. DNL126 reaches the market in 2029 and contributes $150M. The Parkinson's program moves into Phase 3, providing some milestone payments but not yet significant royalties. The company remains cash-flow neutral or slightly negative as it continues to invest heavily in the Alzheimer's pipeline. The implied price of $32.00 represents a convergence with the current analyst average price target.[17, 40, 45, 53]

Low Case (25% Probability):
AVLAYAH launch is crippled by reimbursement delays and competition from gene therapies, peaking at $100M. DNL126 fails its pivotal study. The Parkinson's program (BIIB122) is discontinued after the LUMA readout in 2026. Denali is forced to raise capital at a significant discount, leading to heavy dilution. The company becomes a "fallen angel" valued primarily on its remaining cash and the liquidation value of its patents.[5, 13, 46, 48]

PROBABILITY WEIGHTED PRICE TARGET: $35.85

DE-RISKED GROWTH PIVOT.

6. Qualitative Scorecard

Metric	Score (1-10)	Narrative
Management Alignment	9	CEO Ryan Watts is a co-founder with a 1.4% stake (~$46.5M). Compensation is 89.5% bonuses/equity, aligning him directly with long-term share price performance.[50, 54]
Revenue Quality	5	Improving. Transitioning from "hope and milestones" to high-margin, durable specialty pharma revenue from AVLAYAH.[37, 45]
Market Position	8	First-mover advantage in U.S. BBB-crossing biologics. High validation from the first-ever accelerated approval using the HS biomarker path.[1, 11]
Growth Outlook	9	Excellent. The TV platform can theoretically be applied to any enzyme or antibody, creating a massive "tail" of future indications.[3, 8, 12]
Financial Health	7	Strong cash position (~$1B) and $200M Royalty Pharma payout provides a buffer. However, the burn rate remains a structural concern.[5, 34, 55, 56]
Business Viability	7	Durable technical moat via TfR patents, but high dependence on single-asset binary outcomes for near-term value.[8, 15]
Capital Allocation	8	Sophisticated use of synthetic royalties and public offerings. Re-acquiring DNL593 from Takeda shows a commitment to internal value creation.[31, 57, 58]
Analyst Sentiment	9	Strong consensus (Moderate Buy/Strong Buy). 25 analysts follow the stock with a mean target implying ~85% upside.[38, 40, 53]
Profitability	2	Significant net losses ($512.5M in 2025) and negative free cash flow. Profitability is a post-2029 event in most models.[5, 46]
Track Record	8	Successful execution of the "accelerated approval" strategy and consistent delivery on technical and regulatory milestones.[1, 30]

OVERALL BLENDED SCORE: 7.2 / 10

PLATFORM VALIDATION SECURED.

7. Conclusion & Investment Thesis

Denali Therapeutics represents a unique investment opportunity: a biotechnology company that has solved a 100-year-old biological problem—the blood-brain barrier—and is now entering its commercial prime. The approval of AVLAYAH in March 2026 is the most critical milestone in the company's history, as it validates the "surrogate biomarker" pathway for CNS enzymes and establishes Denali as the first-mover in the $1B+ Hunter syndrome market. The investment thesis for Denali is predicated on three factors: platform validation, modular growth, and asymmetric neurodegenerative upside.

First, the AVLAYAH approval removes the "binary" risk of whether the TV platform works in humans. By reducing CSF heparan sulfate by 91%, Denali has proven its technology can effectively shuttle proteins into the brain and achieve target engagement.[1, 16] Second, the platform's modularity means the path for DNL126 (Sanfilippo) and DNL952 (Pompe) is significantly de-risked and potentially faster, allowing for an "orphan drug conveyor belt" that provides durable, high-margin cash flows.[8, 12] Finally, the current valuation primarily reflects the rare disease franchise, effectively providing a "free option" on the much larger Parkinson's and Alzheimer's programs, which are entering critical data-readout windows in 2026-2027.[3, 4, 27]

Investors must weigh these strengths against the significant capital burn and the execution risk of a first-time commercial launch. However, with ~$1.3 billion in pro-forma cash and a multi-layered patent moat, Denali is the best-positioned company to lead the next decade of CNS medicine. The analysis indicates the stock is currently undervalued relative to its intrinsic platform value.[5, 46, 57]

CNS CATEGORY LEADER.

8. Technical Analysis, Price Action & Short-Term Outlook

Denali is currently trading at $19.45, maintaining its position above the rising 200-day simple moving average (SMA) of $18.30, which confirms a long-term bullish trend.[40, 42, 51] The stock is consolidating after a 27% year-to-date gain, with strong support identified in the $18.77 - $18.96 zone.[39, 51] The neutral RSI of 45.66 and the upcoming Q1 2026 earnings report in May 11 suggest a short-term period of range-bound activity before the next major catalyst—the Parkinson's LUMA readout in mid-2026.[35, 36, 51, 59]

BULLISH LONG-TERM BIAS.

---

1. Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II), https://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-us-fda-approval-avlayahtm
2. Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II) - GlobeNewswire, https://www.globenewswire.com/news-release/2026/03/25/3262412/0/en/Denali-Therapeutics-Announces-U-S-FDA-Approval-of-AVLAYAH-tividenofusp-alfa-eknm-for-Treatment-of-Hunter-Syndrome-MPS-II.html
3. Denali Therapeutics Announces Key Anticipated Milestones and Priorities for 2026 Including Commercial Launch of Tividenofusp Alfa for Hunter Syndrome, https://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-key-anticipated-milestones-and
4. Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta, https://investors.biogen.com/news-releases/news-release-details/biogen-exercises-option-denali-develop-and-commercialize
5. Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights, https://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-reports-fourth-quarter-and-full-year-2025
6. What is Growth Strategy and Future Prospects of Denali Therapeutics Company?, https://portersfiveforce.com/blogs/growth-strategy/denalitherapeutics
7. FDA Approves New Treatment - Project Alive, https://projectalive.org/storage/resources-download/denali-now-approved-fact-sheet-3-25-2026-final-1-69c4768e75073.pdf
8. Science | Denali Therapeutics, https://www.denalitherapeutics.com/science/
9. Sanfilippo Syndrome Market Report 2026 - Research and Markets, https://www.researchandmarkets.com/reports/6226890/sanfilippo-syndrome-market-report
10. Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement, https://investors.denalitherapeutics.com/node/10146/pdf
11. Breaching The Fortress: The New Wave of Companies Cracking The Blood Brain Barrier - Beacon Intelligence, https://beacon-intelligence.com/blog/breaching-the-fortress-the-new-wave-of-companies-cracking-the-blood-brain-barrier/
12. Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights, https://investors.denalitherapeutics.com/node/11226/pdf
13. How AVLAYAH's Accelerated Approval and Takeda Exit Will Impact Denali Therapeutics (DNLI) Investors - Sahm Stock Trading, https://www.sahmcapital.com/news/content/how-avlayahs-accelerated-approval-and-takeda-exit-will-impact-denali-therapeutics-dnli-investors-2026-04-08
14. Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium, https://investors.denalitherapeutics.com/news-releases/news-release-details/denali-therapeutics-announces-data-presentations-enzyme
15. Denali Therapeutics (NASDAQ: DNLI) highlights TV platform, MPS II BLA, https://www.stocktitan.net/sec-filings/DNLI/10-k-denali-therapeutics-inc-files-annual-report-4cd40fb6456d.html
16. FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome, https://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestations-hunter-syndrome
17. Hunter Syndrome Treatment Market Size, Share, Report, 2034 - Fortune Business Insights, https://www.fortunebusinessinsights.com/hunter-syndrome-treatment-market-102536
18. Approval Alert: Avlayah (Tividenofusp Alfa) Gets FDA Nod for Hunter Syndrome, https://antonhealth.com/approval-alert-avlayah-tividenofusp-alfa-gets-fda-nod-for-hunter-syndrome/
19. UX111 for Sanfilippo syndrome type A (MPS IIIA) - Ultragenyx, https://www.ultragenyx.com/our-research/pipeline/ux111-for-mps-iiia/
20. Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics, https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-acquires-global-rights-aav-gene-therapy-abo-102
21. Anti-Parkinson's Drugs: Global Markets to 2030 - BCC Research, https://www.bccresearch.com/market-research/pharmaceuticals/anti-parkinson-drugs-global-markets-report.html
22. Advancing Development of LRRK2-Targeted Therapeutics for Parkinson's Disease: Conference Proceedings and Roadmap for Research - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12978670/
23. Recent advances in targeting LRRK2 for Parkinson's disease treatment - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12235878/
24. Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development - GlobeNewswire, https://www.globenewswire.com/news-release/2026/02/19/3241115/0/en/drug-delivery-breakthroughs-cross-indication-research-accelerate-new-momentum-in-cns-and-oncology-development.html
25. Trontinemab | ALZFORUM, https://www.alzforum.org/therapeutics/trontinemab
26. Trontinemab for Alzheimer's Disease (TRONTIER 1 Trial), https://www.withpower.com/trial/phase-3-alzheimer-disease-9-2025-3b58a
27. Roche presents new insights in Alzheimer's disease research across its diagnostics and pharmaceutical portfolios at AAIC, https://www.roche.com/media/releases/med-cor-2025-07-28
28. Bridging the blood-brain barrier: strategies to improve delivery of biologics to tumors in the brain - PMC, https://pmc.ncbi.nlm.nih.gov/articles/PMC12896330/
29. Global Sanfilippo A Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032, https://www.databridgemarketresearch.com/reports/global-sanfilippo-a-market
30. Stifel raises Denali Therapeutics price target on drug approval - Investing.com, https://www.investing.com/news/analyst-ratings/stifel-raises-denali-therapeutics-price-target-on-drug-approval-93CH-4581050
31. Form 8-K for Denali Therapeutics INC filed 04/03/2026, https://investors.denalitherapeutics.com/static-files/4044091d-c984-4eb8-97ec-11d114d1fa06
32. Takeda tears up Denali partnership, returning dementia asset amid restructuring, https://www.fiercebiotech.com/biotech/takeda-tears-denali-partnership-returning-dementia-asset-amid-restructuring
33. Why Denali Therapeutics (DNLI) Is Up 7.4% After Regaining Full Rights To DNL593 Collaboration - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/why-denali-therapeutics-dnli-is-up-74-after-regaining-full-r
34. Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights, https://investors.denalitherapeutics.com/node/11566/pdf
35. Denali Therapeutics (DNLI) Earnings: Latest Report, Earnings Call & Financials, https://public.com/stocks/dnli/earnings
36. Denali Therapeutics (DNLI) Earnings Date and Reports 2026 - MarketBeat, https://www.marketbeat.com/stocks/NASDAQ/DNLI/earnings/
37. Denali Therapeutics Inc. (DNLI) Earnings Dates & Report | Seeking Alpha, https://seekingalpha.com/symbol/DNLI/earnings
38. DENALI THERAPEUTICS INC (DNLI) Forecast, Price Target & Analyst Ratings - ChartMill, https://www.chartmill.com/stock/quote/DNLI/analyst-ratings
39. FDA approves Denali's Hunter syndrome brain therapy AVLAYAH - Investing.com, https://www.investing.com/news/company-news/fda-approves-denalis-hunter-syndrome-brain-therapy-avlayah-93CH-4580451
40. What is the current Price Target and Forecast for Denali Therapeutics (DNLI) - Zacks Investment Research, https://www.zacks.com/stock/research/DNLI/price-target-stock-forecast
41. Denali Therapeutics DNLI - Analyst Price Targets & Ratings History | AnaChart, https://anachart.com/ticker/dnli/
42. Denali Therapeutics Inc. $DNLI Shares Acquired by Baillie Gifford & Co. - MarketBeat, https://www.marketbeat.com/instant-alerts/filing-denali-therapeutics-inc-dnli-shares-acquired-by-baillie-gifford-co-2026-04-13/
43. Denali Therapeutics (DNLI) Stock Forecast & Price Target - Investing.com, https://www.investing.com/equities/denali-therapeutics-consensus-estimates
44. Q3 EPS Estimate for Denali Therapeutics Increased by Analyst - MarketBeat, https://www.marketbeat.com/instant-alerts/q3-eps-estimate-for-denali-therapeutics-increased-by-analyst-2026-04-09/
45. Assessing Denali Therapeutics (DNLI) Valuation After Recent Share Pullback And Pipeline Growth Expectations, https://www.sahmcapital.com/news/content/assessing-denali-therapeutics-dnli-valuation-after-recent-share-pullback-and-pipeline-growth-expectations-2026-04-10
46. Is It Time To Revisit Denali Therapeutics (DNLI) After Recent Share Price Pullback, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/news/is-it-time-to-revisit-denali-therapeutics-dnli-after-recent
47. Trontinemab Shows Promise for Treatment of Alzheimer Disease in New Data at CTAD, https://www.psychiatrictimes.com/view/trontinemab-shows-promise-for-treatment-of-alzheimer-disease-in-new-data-at-ctad
48. Denali Therapeutics Inc. DCF Valuation | DNLI - MLQ.ai | AI for investors, https://mlq.ai/stocks/DNLI%20%20/dcf/
49. Mucopolysaccharidosis (MPS) Treatment Market Size & Forecast - Coherent Market Insights, https://www.coherentmarketinsights.com/market-insight/mucopolysaccharidosis-treatment-market-4184
50. Denali Therapeutics Inc. (DNLI) Leadership & Management Team Analysis - Simply Wall St, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dnli/denali-therapeutics/management
51. DNLI Technical Analysis | Trend, Signals & Chart Patterns | DENALI THERAPEUTICS INC (NASDAQ:DNLI) | ChartMill.com, https://www.chartmill.com/stock/quote/DNLI/technical-analysis
52. Denali Therapeutics details 2026 shareholder votes | DNLI Proxy Statement - Stock Titan, https://www.stocktitan.net/sec-filings/DNLI/def-14a-denali-therapeutics-inc-definitive-proxy-statement-35dee50bad23.html
53. DNLI / Denali Therapeutics Inc. (NasdaqGS) - Forecast, Price Target, Estimates, Predictions, https://fintel.io/sfo/us/dnli
54. board of directors and cor - Denali Therapeutics, https://investors.denalitherapeutics.com/static-files/5bd95b26-6905-46ba-bae3-0600bd8c1505
55. Form 8-K for Denali Therapeutics INC filed 03/31/2026, https://investors.denalitherapeutics.com/static-files/7efb258a-4cbc-4101-85df-add8053aa8a5
56. Denali Therapeutics (DNLI) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026 - Public Investing, https://public.com/stocks/dnli/forecast-price-target
57. Denali Therapeutics (NASDAQ: DNLI) closes $200M royalty deal after FDA OK, https://www.stocktitan.net/sec-filings/DNLI/8-k-denali-therapeutics-inc-reports-material-event-33a840977500.html
58. December 4, 2025 — Denali Therapeutics Inc. (Nasdaq: DNLI) and Royalty Pharma plc (Nasdaq: RPRX) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. - SEC.gov, https://www.sec.gov/Archives/edgar/data/1714899/000171489925000208/denalitherapeutics2025roya.htm
59. DNLI Technical Analysis, RSI and Moving Averages - Investing.com, https://www.investing.com/equities/denali-therapeutics-technical